

CHAPTER ONE: INTRODUCTION	1
STUDY GOALS AND OBJECTIVES.....	1
REASONS FOR DOING THE STUDY	1
INTENDED AUDIENCE.....	1
SCOPE OF REPORT	2
METHODOLOGY AND INFORMATION SOURCES.....	2
ANALYST CREDENTIALS.....	3
RELATED BCC REPORTS	3
BCC ONLINE SERVICES.....	4
DISCLAIMER	4
 CHAPTER TWO: EXECUTIVE SUMMARY.....	 5
EXECUTIVE SUMMARY.....	5
<i>SUMMARY TABLE GLOBAL PRESCRIPTION AND OTC</i>	
<i>GASTROINTESTINAL DISORDER TREATMENT MARKET,</i>	
<i>THROUGH 2014 (\$ MILLIONS).....</i>	<i>6</i>
<i>SUMMARY FIGURE GLOBAL PRESCRIPTION AND OTC</i>	
<i>GASTROINTESTINAL DISORDER TREATMENT MARKET, 2007-</i>	
<i>2014 (\$ MILLIONS).....</i>	<i>6</i>
 CHAPTER THREE: INDUSTRY OVERVIEW.....	 7
STRUCTURE AND FUNCTION OF THE GASTROINTESTINAL	
SYSTEM.....	7
STRUCTURE AND FUNCTION (CONTINUED)	8
INGESTION AND PROPULSION OF FOOD	9
Mouth	9
Pharynx.....	9
Esophagus	10
DIGESTION AND ABSORPTION	10
Mouth	10
Stomach.....	10
Small Intestines.....	11
Physiology of Digestion	11
Physiology of Digestion (Continued)	12
ELIMINATION	13
Large Intestine	13
LIVER, BILIARY TRACT AND PANCREAS	14
LIVER	14
BILIARY TRACT.....	14
Bilirubin Metabolism.....	15
PANCREAS	15
GASTROINTESTINAL TRACT DISORDERS	15
DYSPHAGIA	15
Dysphagia (Continued).....	16
ESOPHAGEAL AND ABDOMINAL PAIN.....	17

VOMITING	18
INTESTINAL GAS.....	18
CONSTIPATION.....	19
DIARRHEA.....	19
<i>TABLE 1 CAUSES OF DIARRHEA.....</i>	<i>20</i>
GASTROINTESTINAL TRACT WALL DISORDERS	21
GASTRITIS.....	21
<i>TABLE 2 COMMON CAUSES OF GASTRITIS.....</i>	<i>21</i>
GASTROENTERITIS.....	22
PEPTIC ULCER DISEASE	23
Peptic Ulcer Disease (Continued)	24
GASTRIC ULCERS.....	25
DUODENAL ULCERS.....	26
INFLAMMATORY BOWEL DISEASE	27
ULCERATIVE COLITIS.....	28
CROHN'S DISEASE	28
ENTEROCOLITIS.....	29
DIVERTICULAR DISEASE	30
GASTROINTESTINAL TRACT MOTILITY DISORDERS	30
IRRITABLE BOWEL SYNDROME.....	30
INTESTINAL OBSTRUCTION.....	31
GASTROINTESTINAL MALABSORPTION DISORDERS.....	32
CELIAC DISEASE	32
TROPICAL SPRUE.....	33
CANCERS OF THE GASTROINTESTINAL TRACT	33
ESOPHAGEAL CANCER.....	33
GASTRIC CANCER	34
LIVER CANCER	35
PANCREATIC CANCER	36
SMALL INTESTINAL CANCER.....	37
COLONIC POLYPS AND COLON CANCER	37
Colonic Polyps and (Continued)	38
U.S. DEMOGRAPHICS	39
<i>TABLE 3 U.S. ESTIMATED INCIDENCE/PREVALENCE/MORTALITY</i> <i>OF SELECTED GASTROINTESTINAL CONDITIONS</i>	<i>39</i>
<i>TABLE 4 U.S. POPULATION BY SELECTED AGE GROUPS, 2009 AND</i> <i>2014 (THOUSANDS).....</i>	<i>40</i>
<i>FIGURE 1 U.S. POPULATION BY SELECTED AGE GROUPS, 2009</i> <i>AND 2014 (THOUSANDS).....</i>	<i>40</i>
<i>FIGURE 2 U.S. POPULATION SELECTED AGE GROUPS BY</i> <i>PERCENT OF TOTAL POPULATION, 2009 AND 2014 (%).....</i>	<i>41</i>
PILL-SIZED VIDEO CAMERA.....	42
PILLCAM ESO	42
SMARTPILL.....	42

RADIO FREQUENCY IDENTIFICATION TECHNOLOGY.....	43
IPHONE APPLICATION	43
ENTERIC NERVOUS SYSTEM	43
INSURANCE COVERAGE.....	44
MONOCLONAL ANTIBODIES	45
WYETH IN SUIT WITH STATES	46
GENERIC INFLUENCE	46
BRANDED VS OTC PROTON PUMP INHIBITORS	47
MAIL ORDER TRENDS.....	48
MAIL ORDER TRENDS (CONTINUED)	49
 CHAPTER FOUR: PRESCRIPTION PRODUCT SEGMENTS BY TYPE.....	 50
ANTIDIARRHEALS	50
SYSTEMICALLY ACTING ANTIDIARRHEALS.....	51
OPIUM PRODUCTS	51
<i>TABLE 5 MARKETED ANTIDIARRHEAL PRODUCTS</i>	52
MARKET SIZE AND GROWTH.....	52
<i>TABLE 6 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY</i> <i>REGION, THROUGH 2014 (\$ MILLIONS)</i>	53
<i>FIGURE 3 GLOBAL PRESCRIPTION ANTIDIARRHEAL MARKET, BY</i> <i>REGION, THROUGH 2014 (\$ MILLIONS)</i>	53
COMPETITIVE STRUCTURE AND MARKET SHARE.....	54
<i>TABLE 7 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES</i> <i>AND MARKET SHARE LEVELS, BY MANUFACTURER, 2009 (\$</i> <i>MILLIONS/%)</i>	54
<i>FIGURE 4 GLOBAL PRESCRIPTION ANTIDIARRHEAL REVENUES,</i> <i>2009 (\$ MILLIONS)</i>	55
ANTIEMETICS.....	55
LOCALLY ACTING ANTIEMETICS.....	55
CENTRALLY ACTING ANTIEMETICS.....	56
ANTIDOPAMINERGICS.....	56
Antidopaminergics (Continued)	57
ANTICHOLINERGICS	58
MISCELLANEOUS ANTIEMETICS	58
Miscellaneous Antiemetics (Continued)	59
Miscellaneous Antiemetics (Continued)	59
<i>TABLE 8 MARKETED ANTIEMETIC PRODUCTS</i>	60
<i>TABLE 8 (CONTINUED)</i>	61
MARKET SIZE AND GROWTH.....	61
<i>TABLE 9 GLOBAL PRESCRIPTION ANTIEMETIC MARKET BY</i> <i>REGION, THROUGH 2014 (\$ MILLIONS)</i>	61
<i>FIGURE 5 GLOBAL PRESCRIPTION ANTIEMETIC MARKET BY</i> <i>REGION, 2007-2014 (\$ MILLIONS)</i>	62
COMPETITIVE STRUCTURE AND MARKET SHARE.....	62

<i>TABLE 10 GLOBAL PRESCRIPTION ANTIEMETIC REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 (\$ MILLIONS/%)</i>	63
<i>FIGURE 6 GLOBAL PRESCRIPTION ANTIEMETICS REVENUES BY MANUFACTURER, 2009 (\$ MILLIONS)</i>	63
GASTROINTESTINAL CANCER TREATMENTS	63
GASTROINTESTINAL CANCER (CONTINUED).....	64
GASTROINTESTINAL CANCER (CONTINUED).....	65
<i>TABLE 11 MARKETED GASTROINTESTINAL CANCER PRODUCTS</i>	66
MARKET SIZE AND GROWTH.....	66
<i>TABLE 12 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG MARKET BY REGION, THROUGH 2014 (\$ MILLIONS)</i>	66
<i>FIGURE 7 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG MARKET BY REGION, 2007-2014 (\$ MILLIONS)</i>	67
COMPETITIVE STRUCTURE AND MARKET SHARE.....	67
<i>TABLE 13 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG REVENUES AND MARKET SHARE, 2009 (\$ MILLIONS/%)</i>	68
<i>FIGURE 8 GLOBAL PRESCRIPTION GASTROINTESTINAL CANCER DRUG REVENUES, 2009 (\$ MILLIONS)</i>	68
H2 INHIBITORS.....	68
H2 INHIBITORS (CONTINUED)	69
H2 INHIBITORS (CONTINUED)	70
H2 INHIBITORS (CONTINUED)	71
<i>TABLE 14 MARKETED H2 INHIBITORS PRODUCTS</i>	72
MARKET SIZE AND GROWTH.....	72
<i>TABLE 15 GLOBAL PRESCRIPTION H2 INHIBITOR MARKET BY REGION, THROUGH 2014 (\$ MILLIONS)</i>	73
<i>FIGURE 9 GLOBAL PRESCRIPTION H2 INHIBITOR MARKET BY REGION, 2007-2014 (\$ MILLIONS)</i>	73
COMPETITIVE STRUCTURE AND MARKET SHARE.....	73
<i>TABLE 16 GLOBAL PRESCRIPTION H2 INHIBITOR REVENUES AND MARKET SHARE, 2009 (\$ MILLIONS/%)</i>	74
<i>FIGURE 10 GLOBAL PRESCRIPTION H2 INHIBITOR REVENUES, 2009 (\$ MILLIONS)</i>	74
LAXATIVES	74
LAXATIVES (CONTINUED).....	75
<i>TABLE 17 MARKETED LAXATIVE PRODUCTS</i>	76
MARKET SIZE AND GROWTH.....	77
<i>TABLE 18 GLOBAL PRESCRIPTION LAXATIVE MARKET BY REGION, THROUGH 2014 (\$ MILLIONS)</i>	77
<i>FIGURE 11 GLOBAL PRESCRIPTION LAXATIVE MARKET BY REGION, 2007-2014 (\$ MILLIONS)</i>	78
COMPETITIVE STRUCTURE AND MARKET SHARE.....	78
<i>TABLE 19 GLOBAL PRESCRIPTION LAXATIVE REVENUES AND MARKET SHARE, 2009 (\$ MILLIONS/%)</i>	78

<i>FIGURE 12 GLOBAL PRESCRIPTION LAXATIVE REVENUES, 2009 (\$ MILLIONS)</i>	79
PROTON PUMP INHIBITORS.....	79
PROTON PUMP INHIBITORS (CONTINUED)	80
PROTON PUMP INHIBITORS (CONTINUED)	81
<i>TABLE 20 MARKETED PROTON PUMP INHIBITOR PRODUCTS</i>	82
MARKET SIZE AND GROWTH.....	82
<i>TABLE 21 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET BY REGION, THROUGH 2014 (\$ MILLIONS)</i>	82
<i>FIGURE 13 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR MARKET BY REGION, 2007-2014 (\$ MILLIONS)</i>	83
COMPETITIVE STRUCTURE AND MARKET SHARE.....	83
<i>TABLE 22 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 (\$ MILLIONS/%)</i>	84
<i>FIGURE 14 GLOBAL PRESCRIPTION PROTON PUMP INHIBITOR REVENUES BY MANUFACTURER, 2009 (\$ MILLIONS)</i>	84
BOWEL ANTI-INFLAMMATORY.....	84
BOWEL ANTI-INFLAMMATORY (CONTINUED)	85
BOWEL ANTI-INFLAMMATORY (CONTINUED)	86
<i>TABLE 23 MARKETED BOWEL ANTI-INFLAMMATORY PRODUCTS</i>	87
MARKET SIZE AND GROWTH.....	87
<i>TABLE 24 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT MARKET BY REGION, THROUGH 2014 (\$ MILLIONS)</i>	87
<i>FIGURE 15 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT MARKET BY REGION, 2007-2014 (\$ MILLIONS)</i>	88
COMPETITIVE STRUCTURE AND MARKET SHARE.....	88
<i>TABLE 25 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT REVENUES AND MARKET SHARE, 2009 (\$ MILLIONS/%)</i>	89
<i>FIGURE 16 GLOBAL PRESCRIPTION BOWEL INFLAMMATORY AGENT REVENUES BY MANUFACTURER, 2009 (\$ MILLIONS)</i>	89
OTHER GASTROINTESTINAL PRODUCTS.....	89
ANTISPASMODICS.....	90
<i>TABLE 26 MARKETED ANTISPASMODIC PRODUCTS</i>	90
DIGESTANTS	90
GASTRIC ACIDIFIERS.....	91
PANCREATIC ENZYMES.....	91
<i>TABLE 27 MARKETED DIGESTANT PRODUCTS</i>	92
EVACUANTS	92
<i>TABLE 28 MARKETED EVACUANTS PRODUCTS</i>	92
MUCOSAL PROTECTANTS.....	93
<i>TABLE 29 MARKETED MUCOSAL PROTECTANT PRODUCTS</i>	93
PROSTAGLANDINS.....	93
<i>TABLE 30 MARKETED PROSTAGLANDIN PRODUCTS</i>	94

STIMULANTS.....	94
TABLE 31 MARKETED STIMULANT PRODUCTS	94
MARKET SIZE AND GROWTH.....	95
TABLE 32 GLOBAL PRESCRIPTION OTHER GASTROINTESTINAL DRUG MARKET BY REGION, THROUGH 2014 (\$ MILLIONS).....	95
FIGURE 17 GLOBAL PRESCRIPTION OTHER GASTROINTESTINAL DRUG MARKET BY REGION, 2007-2014 (\$ MILLIONS)	95
COMPETITIVE STRUCTURE.....	96
TOTAL GLOBAL PRESCRIPTION GASTROINTESTINAL MARKET SIZE AND GROWTH	96
TABLE 33 GLOBAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES BY CATEGORY, THROUGH 2014 (\$ MILLIONS).....	96
FIGURE 18 GLOBAL PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES BY CATEGORY, 2007-2014 (\$ MILLIONS).....	97
TOTAL U.S. PRESCRIPTION GASTROINTESTINAL COMPETITIVE ANALYSIS	97
TABLE 34 MANUFACTURERS MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES, (ESTIMATED 2009).....	98
FIGURE 19 MANUFACTURERS MARKET SHARE OF PRESCRIPTION GASTROINTESTINAL DISORDER TREATMENT REVENUES, 2009 ESTIMATED (%)......	99
CHAPTER FIVE: OTC PRODUCT SEGMENTS BY TYPE.....	100
ANTACIDS.....	100
SYSTEMIC ANTACIDS.....	101
Sodium Bicarbonate	101
NONSYSTEMIC ANTACIDS	101
Calcium Carbonate.....	101
Aluminum Products.....	102
Magnesium Products	102
Combination Products	103
TABLE 35 MARKETED OTC ANTACID PRODUCTS.....	103
TABLE 35 (CONTINUED).....	104
MARKET SIZE AND GROWTH.....	104
TABLE 36 GLOBAL OTC ANTACID MARKET BY REGION, THROUGH 2014 (\$ MILLIONS).....	104
FIGURE 20 GLOBAL OTC ANTACID MARKET BY REGION, 2007-2014 (\$ MILLIONS).....	105
COMPETITIVE STRUCTURE AND MARKET SHARE.....	105
TABLE 37 GLOBAL OTC ANTACID REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 (\$ MILLIONS/%)	106

<i>FIGURE 21 GLOBAL OTC ANTACID MARKET SHARE BY MANUFACTURER, 2009 (%).....</i>	<i>106</i>
LOCALLY ACTING ANTIDIARRHEALS	106
ADSORBENTS	107
INTESTINAL FLORA MODIFIERS	108
<i>TABLE 38 MARKETED OTC ANTIDIARRHEAL PRODUCTS</i>	<i>108</i>
MARKET SIZE AND GROWTH.....	108
<i>TABLE 39 GLOBAL OTC ANTIDIARRHEALS MARKET BY REGION, THROUGH 2014 (\$ MILLIONS).....</i>	<i>109</i>
<i>FIGURE 22 GLOBAL OTC ANTIDIARRHEALS MARKET BY REGION, 2007-2014 (\$ MILLIONS).....</i>	<i>109</i>
COMPETITIVE STRUCTURE AND MARKET SHARE.....	110
<i>TABLE 40 GLOBAL OTC ANTIDIARRHEALS REVENUES BY MANUFACTURER, 2009 (\$ MILLIONS/%)</i>	<i>110</i>
<i>FIGURE 23 GLOBAL OTC ANTIDIARRHEALS MARKET SHARE BY MANUFACTURER, 2009 (%).....</i>	<i>110</i>
H2 INHIBITORS.....	111
H2 INHIBITORS (CONTINUED)	112
H2 INHIBITORS (CONTINUED)	113
<i>TABLE 41 MARKETED OTC H2 INHIBITORS PRODUCTS</i>	<i>114</i>
MARKET SIZE AND GROWTH.....	114
<i>TABLE 42 GLOBAL OTC H2 INHIBITOR MARKET BY REGION, THROUGH 2014 (\$ MILLIONS).....</i>	<i>114</i>
<i>FIGURE 24 GLOBAL OTC H2 INHIBITOR MARKET BY REGION, 2007-2014 (\$ MILLIONS).....</i>	<i>115</i>
COMPETITIVE STRUCTURE AND MARKET SHARE.....	115
<i>TABLE 43 GLOBAL OTC H2 INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 (\$ MILLIONS/%)</i>	<i>116</i>
<i>FIGURE 25 GLOBAL OTC H2 INHIBITOR MARKET SHARE BY MANUFACTURER, 2009 (%).....</i>	<i>116</i>
PROTON PUMP INHIBITORS.....	116
OMEPRAZOLE (PRILOSEC, PROCTER & GAMBLE)	116
<i>TABLE 44 MARKETED OTC PROTON PUMP INHIBITOR PRODUCTS</i>	<i>117</i>
MARKET SIZE AND GROWTH.....	117
<i>TABLE 45 GLOBAL OTC PROTON PUMP INHIBITOR MARKET BY REGION, THROUGH 2014 (\$ MILLIONS)</i>	<i>118</i>
<i>FIGURE 26 GLOBAL OTC PROTON PUMP INHIBITOR MARKET BY REGION, 2007-2014 (\$ MILLIONS).....</i>	<i>118</i>
COMPETITIVE STRUCTURE AND MARKET SHARE.....	119
<i>TABLE 46 GLOBAL OTC PROTON PUMP INHIBITOR REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 (\$ MILLIONS/%).....</i>	<i>119</i>
<i>FIGURE 27 GLOBAL OTC PROTON PUMP INHIBITOR MARKET SHARE BY MANUFACTURER, 2009 (%).....</i>	<i>119</i>

LAXATIVES	120
TABLE 47 MARKETED OTC LAXATIVE PRODUCTS	120
TABLE 47 (CONTINUED).....	121
MARKET SIZE AND GROWTH.....	121
TABLE 48 GLOBAL OTC LAXATIVES MARKET BY REGION, THROUGH 2014 (\$ MILLIONS).....	121
FIGURE 28 GLOBAL OTC LAXATIVE MARKET BY REGION, 2007-2014 (\$ MILLIONS).....	122
COMPETITIVE STRUCTURE AND MARKET SHARE.....	122
TABLE 49 GLOBAL OTC LAXATIVE REVENUES AND MARKET SHARE BY MANUFACTURER, 2009 (\$ MILLIONS/%)	122
FIGURE 29 GLOBAL OTC LAXATIVE MARKET SHARE BY MANUFACTURER, 2009 (%).....	123
TOTAL OTC GASTROINTESTINAL DRUG MARKET SIZE AND GROWTH	123
TABLE 50 GLOBAL OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY PRODUCT CATEGORY, THROUGH 2014 (\$ MILLIONS).....	123
FIGURE 30 GLOBAL OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY PRODUCT CATEGORY, 2007-2014 (\$ MILLIONS).....	124
TOTAL OTC GASTROINTESTINAL DRUG COMPETITIVE ANALYSIS	124
TABLE 51 TOTAL MANUFACTURERS' REVENUES AND MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS, ESTIMATED 2009 (\$ MILLIONS/%)	125
FIGURE 31 TOTAL MANUFACTURERS' MARKET SHARE OF OTC GASTROINTESTINAL DISORDER TREATMENTS, ESTIMATED 2009 (%).....	125
RESEARCH AND DEVELOPMENT	125
METOSOLV ODT.....	126
NEXIUM LOW-DOSE ASPIRIN COMBINATION	126
REZONIC.....	126
SANVAR	126
TAK-390MR (KAPIDEX)	126
ZENPEP.....	127
AB-1001	127
ALICAFORSEN.....	127
APF 530	128
CROFELEMER	128
HUMIRA.....	128
LINACLOTIDE	128
METHYLNALTREXONE (MNTX) (RELSTAR)	128
MLN 0002 (VEDOLIZUMAB).....	129

ORBEC.....	129
PROCHYMAL.....	129
RENZAPRIDE.....	129
REMICADE.....	130
REZULAR.....	130
RIFAXIMAN (XIFAXAN).....	130
SUTENT.....	130
ALICAFORSEN ENEMA.....	130
DEXTOFISOPAM.....	131
EKB-569.....	131
GTI-2040.....	131
PUMOSETRAG.....	131
RDP-58.....	132
SORAPRAZAN.....	132
TALNETANT.....	132
BL-1030.....	132
BL-1050.....	132
<i>TABLE 52 GASTROINTESTINAL DISORDER TREATMENTS IN DEVELOPMENT.....</i>	<i>133</i>
<i>TABLE 52 (CONTINUED).....</i>	<i>134</i>
<i>TABLE 52 (CONTINUED).....</i>	<i>135</i>
<i>TABLE 52 (CONTINUED).....</i>	<i>136</i>
<i>TABLE 52 (CONTINUED).....</i>	<i>137</i>
<i>TABLE 52 (CONTINUED).....</i>	<i>138</i>
<i>TABLE 52 (CONTINUED).....</i>	<i>139</i>
TOTAL MARKET ANALYSIS.....	139
<i>TABLE 53 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER MARKET BY CATEGORY, THROUGH 2014 (\$ MILLIONS).....</i>	<i>139</i>
<i>FIGURE 32 GLOBAL PRESCRIPTION AND OTC GASTROINTESTINAL DISORDER TREATMENT MARKET BY CATEGORY, 2007-2014 (\$ MILLIONS).....</i>	<i>140</i>
CHAPTER SIX: INDUSTRY PARTICIPANTS BY PRODUCT TYPE.....	141
<i>TABLE 54 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS' REVENUES AND MARKET SHARE BY TYPE, 2009 (\$ MILLIONS/%).....</i>	<i>141</i>
<i>FIGURE 33 GASTROINTESTINAL DISORDER TREATMENT MANUFACTURERS' MARKET SHARE BY TYPE, 2009 (%).....</i>	<i>142</i>
COMPANY PROFILES.....	142
ASTRAZENECA.....	142
History.....	143
AXCAN PHARMA, INC.....	143
History.....	144
CENTOCOR, INC.....	145

History.....	146
EISAI, INC.	146
History.....	147
GENENTECH, INC.	147
History.....	148
GLAXOSMITHKLINE	148
Glaxosmithkline (Continued).....	149
Glaxosmithkline (Continued).....	150
History.....	151
JOHNSON & JOHNSON.....	151
History.....	151
MCNEIL CONSUMER HEALTHCARE	152
History.....	152
MERCK & CO., INC.....	152
History.....	153
NOVARTIS INTERNATIONAL AG	153
History.....	154
PFIZER, INC.	154
History.....	155
PROCTER & GAMBLE CO.	155
History.....	156
ROCHE	156
History.....	157
SANOFI-AVENTIS	157
History.....	157
SALIX PHARMACEUTICALS, LTD.....	158
History.....	158
SOLVAY PHARMACEUTICALS	159
History.....	159
TAKEDA PHARMACEUTICALS NORTH AMERICA.....	160
History.....	160
WYETH.....	161
History.....	162

APPENDIX: CONTACT INFORMATION FOR GASTROINTESTINAL

MARKET PARTICIPANTS.....	163
3M CORP.....	163
ABBOTT LABORATORIES.....	163
ABEILLE PHARMA, INC.	163
ACAMBIS, PLC.....	163
ACE BIOSCIENCES A/S.....	163
AGI THERAPEUTICS, INC.	163
ALCHEMIA, LTD.	164
ALIZYME, PLC.....	164
ALLERGAN, INC.....	164

ALLSCRIPTS HEALTHCARE SOLUTIONS, INC.	164
ALTANA PHARMA AG	164
ALVINE PHARMACEUTICALS, INC.	164
AMARIN CORP.	164
AMGEN, INC.	165
ANTIGENICS, INC.	165
APOTHECON B.V.	165
AP PHARMA, INC.	165
ARCO PHARMACEUTICALS	165
ASPHELIA PHARMACEUTICALS, INC.	165
ARYX THERAPEUTICS, INC.	165
ASTELLAS PHARMA, INC.	166
ASTRAZENECA, PLC	166
AXCAN PHARMA, INC.	166
BERTEK (MYLAN LABORATORIES INC.)	166
BIOBALANCE, INC.	166
BIOGEN IDEC, INC.	166
BIOLINERX, LTD.	167
BRAINTREE LABORATORIES, INC.	167
BRISTOL-MYERS SQUIBB CO.	167
CELLDEX THERAPEUTICS, INC.	167
CENTOCOR ORTHO BIOTECH, INC.	167
CEPHALON, INC.	167
CERIMON PHARMA, INC.	167
CHEMOCENTRYX, INC.	168
CLAVIS PHARMA ASA	168
COSMO PHARMACEUTICALS SPA	168
CYTOKINE PHARMASCIENCES, INC.	168
DEBIOPHARM S.A.	168
DOR BIOPHARMA, INC.	168
EISAI CO., LTD.	169
ELAN CORPORATION, PLC	169
EMD SERONO, INC.	169
ENZO	169
EURAND PHARMACEUTICALS, INC.	169
EVOKE PHARMA	169
FRESENIUS KABI AG	169
GENENTECH, INC.	170
GENZYME GENERAL	170
GLAXOSMITHKLINE, PLC	170
GLAXOSMITHKLINE CONSUMER HEALTHCARE	170
GLENMARK PHARMACEUTICALS, LTD.	170
H3 PHARMA, INC.	170
HELSINN HEALTHCARE	171

HOFFMAN-LAROCHE, LTD. (ROCHE)	171
HYPERION THERAPEUTICS, INC.....	171
IMMUCELL CORP.	171
ISIS PHARMACEUTICALS. INC.....	171
JANSSEN PHARMACEUTICA PRODUCTS, LP (JOHNSON & JOHNSON)	171
JOHNSON & JOHNSON	171
LORUS THERAPEUTICS, INC.....	172
MCNEIL CONSUMER & SPECIALTY PHARMACEUTICALS	172
MEDISCA, INC.....	172
MERCK & CO., INC.	172
MONARCH LABS.....	172
NABI BIOPHARMACEUTICALS	172
NOVARTIS CORP.....	172
NPS PHARMACEUTICALS, INC.....	173
OTSUKA AMERICA PHARMACEUTICAL, INC.	173
PFIZER, INC.....	173
THE PROCTER & GAMBLE CO.	173
PRODIGENE, INC.....	173
PROGENICS PHARMACEUTICALS, INC.	173
RAVEN BIOTECHNOLOGIES, INC.....	173
RELIANT PHARMACEUTICALS, INC.	174
ROXANE LABORATORIES, INC.....	174
SALIX PHARMACEUTICALS, LTD.....	174
SANOFI-AVENTIS	174
SANTARUS, INC.....	174
SCHERING AG.....	174
SCHWARZ PHARMA AG.....	174
SERONO S.A.....	175
SHIRE PHARMACEUTICALS GROUP, PLC.....	175
SOLVAY S.A.	175
SUCAMPO PHARMACEUTICALS, INC.	175
SWISS AGENCY FOR THERAPEUTIC PRODUCTS (SWISSMEDIC)	175
TAKEDA PHARMACEUTICAL NORTH AMERICA	175
TARGACEPT, INC.....	176
THERAVANCE, INC.....	176
UCB PHARMA, INC.....	176
UNIMED PHARMACEUTICALS, INC.	176
PHARMOS PHARMACEUTICALS, INC.	176
WATSON PHARMACEUTICALS, INC.....	176
WYETH (WHITEHALL-ROBINS HEALTHCARE, INC.)	176